PROVO, Utah--(BUSINESS WIRE)--GeNOsys, Inc. (OTCBB: GNYS) today announced the signing of a Service Contract with the University of British Columbia (“UBC”). The Service Contract is for a period of one year. Under the Service Contract, UBC will conduct research at the UBC Department of Medicine, and the Vancouver Coastal Health Research Institute, which conducts and coordinates research in support of international programs for infectious disease control and prevention. The research will be conducted under the direction of Dr. Yossef Av-Gay. Dr. Av-Gay’s laboratory research is focused on the molecular pathogenesis of Mycobacterium tuberculosis (“TB”) and identification of new targets for drug therapy. Dr. Av-Gay is universally recognized as one of the foremost authorities on TB. He is sought after as a speaker and presenter at medical conferences around the world and has authored numerous publications. Dr. Av-Gay led the team that recently discovered that the TB bacteria protects itself in the human cell by secreting a protein in the cell that disrupts the nitric oxide process the body normally uses to destroy invading bacteria. This allows the TB bacteria to hide and multiply. The results of this groundbreaking discovery were published in the May 2008 issue of Cell Press. Dr. Av-Gay will lead the team conducting research on the treatment of TB with nitric oxide, utilizing the patented nitric oxide generator and the proprietary nitric oxide generating tablets manufactured by GeNOsys. Dr. Av-Gay is a recognized expert and reviewer for projects related to TB drug development, which has a stated goal to eradicate TB. There are more than ten million new cases of tuberculosis annually, causing more than three million deaths each year. TB is the leading bacterial cause of human mortality in the world.
